1 hour ago
1
MarketBeat
Wed, March 4, 2026 astatine 9:36 AM CST 9 min read
-
DURAVYU progress: Eyepoint has dosed the archetypal patients successful pivotal Phase 3 DME trials and expects top-line Phase 3 bedewed AMD information opening successful mid-2026, positioning DURAVYU arsenic a imaginable six-month intravitreal attraction with a multi‑MOA (VEGF/PDGF/IL‑6 via JAK1) profile.
-
Safety illustration and monitoring: Across ~190 patients successful anterior studies the institution reports nary caller information signals, debased intraocular inflammation (~1%), and cataract/floaters rates comparable to control, with ongoing interior masked reviews and autarkic DMC oversight.
-
Financials and runway: Year-end currency and investments were $306 cardinal (after a $173M October financing), which absorption says funds operations into Q4 2027, but 2025 revenues fell and operating expenses roseate materially owed to Phase 3 activity, widening the nett loss.
-
Interested successful Eyepoint Pharmaceuticals, Inc.? Here are 5 stocks we similar better.
-
Breakout Momentum Plays You May Not Know About
Eyepoint Pharmaceuticals (NASDAQ:EYPT) outlined late-stage objective advancement for its pb retinal campaigner DURAVYU and reviewed fourth-quarter and full-year 2025 fiscal results connected its net call, emphasizing upcoming information readouts successful bedewed age-related macular degeneration (wet AMD) and the commencement of pivotal studies successful diabetic macular edema (DME).
President and CEO Dr. Jay Duker said 2025 featured “significant progress” and that DURAVYU is connected way to present top-line information successful bedewed AMD “beginning successful mid-2026.” He added that the institution has present dosed the archetypal patients successful some pivotal Phase 3 DME trials arsenic of past week.
→ Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the Gap
Duker described DURAVYU’s objective illustration based connected completed studies and ongoing blinded reviews. Across much than 190 patients successful 1 Phase 1 and 3 Phase 2 trials, helium said the programme has shown “no information signals,” and helium noted the information illustration remains accordant successful the ongoing Phase 3 LUGANO and LUCIA bedewed AMD trials based connected masked interior reappraisal and 2 interim autarkic Data Safety Monitoring Committee (DMC) reviews.
Duker highlighted the company’s presumption that DURAVYU’s differentiation is driven by the imaginable for six-month dosing via modular in-office intravitreal injection, the transportation technology, and a “novel multi-MOA” that inhibits VEGF, PDGF, and IL-6 via JAK1, with nary TIE-2 inhibition. He said this illustration could code some VEGF-mediated vascular leakage and IL-6-mediated inflammation successful bedewed AMD and DME.
→ IonQ successful Rebound Mode: Buy the Thesis, Respect the Risk
English (CA) · 
English (US) · 
Spanish (MX) ·